Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study)

A 52-week Extension to the Factorial Study to Evaluate the Efficacy and Safety of VAH631 (Valsartan and Hydrochlorothiazide Combined) and Alone in Essential Hypertensive Patients - Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study) -

This study is designed to provide long-term safety and efficacy data for the combination doses of VAH (VAL/ HCTZ) 40/6.25mg and 80/12.5mg in essential hypertensive patients. The 350 patients (approximately) who have successfully finished the core trial CVAH631B1303 and signed consent for the extension will be enrolled into this study.

Inclusion Criteria:

• Patients who successfully complete the core study (Protocol 1303)
• Outpatients

Exclusion Criteria:

• Presence of crucial protocol violation in Protocol 1303
• Patients who experienced any adverse events considered serious and drug related in Protocol 1303.